Drug Profile
Zectivimod - LG Chem
Alternative Names: LC-510255; LR-19019Latest Information Update: 03 Nov 2023
Price :
$50
*
At a glance
- Originator LG Life Sciences
- Developer LG Chem
- Class Anti-inflammatories; Carboxylic acids; Chlorine compounds; Ethers; Indazoles; Naphthalenes; Piperidines; Skin disorder therapies; Small molecules
- Mechanism of Action Sphingosine 1 phosphate receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Atopic dermatitis; Ulcerative colitis
Most Recent Events
- 03 Nov 2023 Chemical structure information added
- 20 Oct 2023 Zectivimod is available for licensing as of 20 Oct 2023. https://innovation.lgchem.com/ResearchDevelopment/Partnership.do (LG Chem wesbite, October 2023)
- 20 Oct 2023 Phase-II clinical trials in Atopic dermatitis in China (PO) prior to October 2023 (LG Chem pipeline, October 2023)